Analyst Ratings For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Today, Stifel Nicolaus reiterated its Buy rating on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) with a price target of $23.00.
There are 3 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is Hold with a consensus target price of $24.60 per share, a potential 112.62% upside.
Some recent analyst ratings include
- 7/31/2018-Stifel Nicolaus Reiterated Rating of Buy .
- 7/30/2018-Needham & Company LLC Reiterated Rating of Hold.
- 6/18/2018-Wedbush Reiterated Rating of Buy.
- 2/14/2018-JPMorgan Chase & Co. was Downgraded by analysts at JPMorgan Chase & Co. from a “Neutral ” rating to a ” Underweight” rating. They now have a $10.00 price target on the stock, up previously from $15.00 .
- 8/1/2017-Cowen Reiterated Rating of Hold.
- On 6/28/2018 Public Equities L.P. Invus, Director, bought 182,838 with an average share price of $12.51 per share and the total transaction amounting to $2,287,303.38.
- On 6/25/2018 Public Equities L.P. Invus, Director, bought 253,725 with an average share price of $12.99 per share and the total transaction amounting to $3,295,887.75.
- On 6/21/2018 Public Equities L.P. Invus, Director, bought 72,973 with an average share price of $13.29 per share and the total transaction amounting to $969,811.17.
- On 6/18/2018 Public Equities L.P. Invus, Director, bought 45,784 with an average share price of $12.98 per share and the total transaction amounting to $594,276.32.
- On 6/14/2018 Public Equities L.P. Invus, Director, bought 9,200 with an average share price of $12.66 per share and the total transaction amounting to $116,472.00.
- On 6/11/2018 Public Equities L.P. Invus, Director, bought 98,626 with an average share price of $12.75 per share and the total transaction amounting to $1,257,481.50.
- On 6/8/2018 James F Tessmer, VP, sold 10,000 with an average share price of $12.91 per share and the total transaction amounting to $129,100.00.
About Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Recent Trading Activity for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Shares of Lexicon Pharmaceuticals, Inc. closed the previous trading session at 11,74 +0,31 2,71 % with 377113 shares trading hands.